Development of Dalbavancin, a glycopeptide anti-bacterial agent
Location: United States, Illinois, Chicago
Investors 4
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Aisling Ca... | aislingcap... |
| - | Vivo Capit... | vivocapita... |
| - | New Leaf V... | nlvpartner... |
Mentions in press and media 3
| Date | Title | Description |
| 04.12.2012 | New broad-spectrum antibiotic based on Nobel Prize-winning research reaches phase 3 | The drug has been tested in more than 1,200 patients in four phase 2 trials, where it’s shown promising results in the treatment of pneumonia, bronchitis and skin infections. It’s being developed in oral and IV formulations so that patients... |
| 14.11.2012 | Little Durata's relocation plans reap incentives with big staffing promises | Fresh from raising $74 million in an IPO, Durata Therapeutics ($DRTX) is shaking off the dust of Morristown, NJ, and setting a course for Chicago while making big plans for its late-stage antibiotic for skin infections. Durata sold the IPO ... |
| - | New broad-spectrum antibiotic based on Nobel Prize-winning research reaches phase 3 | Three years ago, Yale University professor of molecular biophysics and biochemistry Thomas Steitz won the Nobel Prize in chemistry for his research on the structure and function of the ribosome. Now, the company that he co-founded to create... |